Gilead Beats Q2 Views On Revenue Growth Lead By Sovaldi Drug
July 24, 2014 at 06:50 AM EDT
Gilead Sciences Inc. (Nasdaq: GILD) beat second-quarter expectations on rapid revenue growth lead by sales of its Sovaldi drug for ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.